share_log

Sanofi | 6-K: Sanofi Announces Agreement for Potential First-in-Class Vaccine Against Extraintestinal Pathogenic E. Coli and Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

SEC announcement ·  Oct 11, 2023 06:05
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more